Skip to Content
Merck

Silencing of Eps8 inhibits in vitro angiogenesis.

Life sciences (2015-04-22)
Elisa Cappellini, Claudia Vanetti, Lucia M Vicentini, Maria Grazia Cattaneo
ABSTRACT

Eps8 is an actin-binding protein which has been proposed as a regulator of cancer cell motility and invasion. However, nothing much is known about its contribution to the invasive properties of endothelial cells (ECs), and more generally to angiogenesis. Expression and silencing of Eps8 were evaluated by western blot analysis. The effect of Eps8 silencing on cell number and VEGF-induced signaling was tested with standard methods. Migration was evaluated by scratch wound assay and morphogenesis with 2-dimensional (2-D) tube formation and 3-dimensional (3-D) sprouting assays. Actin cytoskeleton was visualized by immunofluorescence. We found that silencing of Eps8 profoundly affected the ability of human ECs to migrate and to undergo tube formation and sprouting in 2-D and 3-D in vitro assays, respectively. Notably, capillary-like outgrowth was strictly depending on Eps8 expression also in human tumor-derived ECs. Our data demonstrate for the first time the involvement of Eps8 in the morphological processes required for in vitro angiogenesis, and suggest that this protein might represent a common target for the design of new anticancer drugs, acting at the same time on both tumor and endothelial cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Bromo-2′-deoxyuridine, ≥99% (HPLC)
Sigma-Aldrich
5-Bromo-2′-deoxyuridine, BioUltra, ≥99%
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Eps8
Sigma-Aldrich
MISSION® esiRNA, targeting human EPS8
Sigma-Aldrich
Phenylacetic acid, 99%
Sigma-Aldrich
Phenylacetic acid, ≥99%, FCC, FG